Fig. 1
From: A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease
A The study design describes 3 phases of our study: discovery, validation and further validation. B Bile samples within the patient cohorts specified by disease type (CCA, cholangiocarcinoma; AC, ampullary carcinoma; PDAC, pancreatic ductal adenocarcinoma; IPMC, PDAC originating from intraductal papillary mucinous neoplasm; CP, chronic pancreatitis). C Bile samples were collected from laparoscopic cholecystectomy and open pancreatoduodenectomy (PD) for microRNA profiling. D Venn diagrams describing differentially expressed microRNAs (miRNAs) in the discovery cohort, when comparing BPD to MPD